Chengdu Easton Bio Pharmaceuticals Co.Ltd(688513)
Opinions of independent directors on matters related to the second meeting of the third board of directors
Prior approval opinion
As an independent director of Chengdu Easton Bio Pharmaceuticals Co.Ltd(688513) (hereinafter referred to as “the company”), in accordance with the company law of the people’s Republic of China (hereinafter referred to as “the company law”), the Listing Rules of Shanghai Stock Exchange on the science and innovation board, the guiding opinions on the establishment of independent director system in listed companies, the articles of association and the working system of independent directors of the company, and other relevant provisions With a serious and responsible attitude and based on the position of independent judgment, all shareholders and investors express their prior approval opinions on the proposal on the prediction of daily connected transactions of the company in 2022 to be considered at the second meeting of the third board of directors of the company, as follows:
This connected transaction is necessary for the company’s normal production and business activities and an important means for the company to make rational use of resources. The pricing policies of various daily related party transactions will strictly follow the general commercial principles of openness, fairness, impartiality and compensation for equal value, which is conducive to the development of relevant businesses of the company and does not harm the interests of the company and shareholders, especially minority shareholders. We agree to submit the related party transactions to the second meeting of the third board of directors of the company for deliberation.
Independent directors: Jin Li, Fang Fang, Shang Shu March 18, 2022
